Sotera Health Company (SHC) P/E Ratio History
UndervaluedTrading at 66.7x vs 5Y avg 151.6x · 50th percentile · Below historical baseline · Data 2021–2026
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, Sotera Health Company (SHC) trades at a price-to-earnings ratio of 66.7x, with a stock price of $18.02 and trailing twelve-month earnings per share of $0.41.
The current P/E is 56% below its 5-year average of 151.6x. Over the past five years, SHC's P/E has ranged from a low of 15.5x to a high of 1211.5x, placing the current valuation at the 50th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.4x, SHC trades at a 186% premium to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.
Relative to the broader market, SHC commands a significant premium over the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SHC DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SHC Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
SHC P/E vs Peers
Clinical and Specialty Lab Testing peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $24B | 82.8 | 1.87 | +13% | |
| $13B | 58.2 | - | -70% | |
| $16B | 35.8 | 1.12 | +21% | |
| $2B | 128.5 | - | -79% | |
| $4B | 22.1Lowest | 0.37Best | +29%Best | |
| $57B | 26.8 | 1.62 | -1% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
SHC Historical P/E Data (2021–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $14.34 | $0.41 | 35.2x | -77% |
| FY2025 Q4 | Dec 31 2025 | $17.64 | $0.27 | 65.1x | -57% |
| FY2025 Q3 | - | $15.73 | $0.19 | 80.8x | -47% |
| FY2025 Q2 | Jun 30 2025 | $11.12 | $0.08 | 132.2x | -13% |
| FY2025 Q1 | Mar 31 2025 | $11.66 | $0.09 | 134.2x | -11% |
| FY2024 Q4 | - | $13.68 | $0.16 | 87.7x | -42% |
| FY2024 Q3 | Sep 30 2024 | $16.70 | $0.25 | 66.2x | -56% |
| FY2024 Q2 | Jun 30 2024 | $11.87 | $0.14 | 82.3x | -46% |
| FY2024 Q1 | Mar 31 2024 | $12.01 | $0.20 | 61.2x | -60% |
| FY2023 Q4 | Dec 31 2023 | $16.85 | $0.18 | 91.6x | -40% |
| FY2022 Q3 | Sep 30 2022 | $6.82 | $0.44 | 15.5x | -90% |
| FY2022 Q2 | - | $19.59 | $0.45 | 43.5x | -71% |
| FY2022 Q1 | - | $21.66 | $0.49 | 44.2x | -71% |
| FY2021 Q4 | Dec 31 2021 | $23.55 | $0.42 | 56.1x | -63% |
| FY2021 Q3 | - | $26.13 | $0.12 | 217.8x | +44% |
| FY2021 Q2 | Jun 30 2021 | $24.23 | $0.02 | 1211.5x | +699% |
Average P/E for displayed period: 151.6x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SHC — Frequently Asked Questions
Quick answers to the most common questions about buying SHC stock.
What is SHC's P/E ratio?
Sotera Health Company (SHC) trailing twelve-month P/E ratio is 66.7x, based on TTM diluted EPS of $0.41. The 5-year average P/E is 151.6x and the historical range spans 15.5x to 1211.5x.
Is SHC stock overvalued or undervalued?
SHC trades at 66.7x P/E, below its 5-year average of 151.6x. At the 50th percentile of its historical range (15.5x–1211.5x), the stock is priced at a discount to its own history.
Is SHC stock expensive?
No, SHC is not expensive on a historical basis. The current P/E of 66.7x is below the 5-year average of 151.6x and sits at the 50th percentile of its valuation range.
What is SHC's historical P/E range?
Over the past 5 years, SHC's P/E ratio has ranged from 15.5x to 1211.5x, with a median of 80.8x and an average of 151.6x. The current P/E of 66.7x places the stock at the 50th percentile of this range. Full historical data spans 2021–2026.
How does SHC's P/E compare to the S&P 500?
SHC trades at 66.7x P/E versus the S&P 500 median of 25.9x. The 158% premium to the market typically reflects higher expected earnings growth or quality.
How does SHC's valuation compare to Healthcare peers?
Sotera Health Company P/E of 66.7x compares to the Healthcare sector median of 23.4x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is SHC's PEG ratio?
SHC PEG ratio is N/A, based on a P/E of 66.7x and EPS growth of 68.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is SHC's earnings yield?
SHC earnings yield is 1.50%, the inverse of its 66.7x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.